A clinically proven cure for dementia is approved before 2032.

Question

Six frontier AI models put this at 6% by 1 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

6% — the median of 6 frontier models, resolving by 2036-10-01.

Answer

Gemini (Google): 4% — Clinical pipelines contain drugs that slow cognitive decline, but zero candidates in Phase 2 or 3 demonstrate disease reversal or arrest. A drug approving before 2032 would need to be entering Phase 3 today; current late-stage candidates only achieve modest slowing. Regulators like the FDA require multi-year endpoints to prove full disease arrest, leaving insufficient runway before the 2032 deadline. Proof of substantial neuronal regeneration or complete tau arrest in humans within two years would force an upward revision.

Answer

Claude (Anthropic): 4% — Requires an approved therapy that reverses or fully halts dementia pathology, not just slows decline—no candidate is near that bar. Current approved drugs (lecanemab, donanemab) only modestly slow decline, far short of reversal or full arrest, and show no sign of hitting that bar by 2036. Dementia has dozens of underlying etiologies (Alzheimer's, vascular, Lewy body, frontotemporal), making a single 'cure' biologically implausible within a decade. A breakthrough disease-modifying therapy with near-complete efficacy would need to emerge from early-stage research, clear Phase 3 trials, and gain FDA/EMA…

Answer

GPT (OpenAI): 18% — It turns on whether an amyloid/tau or genetic therapy can show durable disease arrest in long, controlled trials by the early 2030s. FDA, EMA, or another major regulator must accept evidence of reversal or full arrest, a far higher bar than current slowing approvals. Alzheimer’s drug development has a long failure history; lecanemab and donanemab modestly slow decline rather than halt disease. Odds rise sharply if prevention trials show multi-year arrest in biomarker-positive patients and regulators accept that endpoint.

Answer

Grok (xAI): 7% — Whether any late-stage trial shows reversal or complete halt of neurodegeneration in time for 2031 approval. FDA/EMA require completed Phase 3 data by ~2030; current agents (lecanemab, donanemab) only modestly slow decline. Zero true neurodegenerative cures have ever been approved; 5-year window sits far below that base rate. A surprise Phase 3 gene-therapy or anti-tau success showing actual reversal would most change the odds.

Answer

DeepSeek (DeepSeek): 7% — Dementia biology is too heterogeneous and slow-moving for a true disease-reversing approval inside a decade. Lecanemab and donanemab cleared FDA in 2023-24 but only slow decline ~27-35%, not reverse or arrest disease, so the bar remains unmet. Anti-amyloid failures span 20+ years and 30+ Phase 3 trials; a genuine cure needs a new target plus 8-12 years of trials and regulatory review. Blood biomarkers and tau PET now enable earlier trials, modestly raising odds above the ~2% historical base rate for neurodegeneration cures.

Answer

Qwen (Alibaba): 4% — No approved therapy has ever reversed or fully arrested dementia pathology; the pipeline is years from even partial disease modification. Lecanemab and donanemab slow decline ~27-35% but do not reverse or arrest disease; no Phase III candidate targets full reversal or arrest. Even if a breakthrough compound entered Phase III today, regulatory approval would require 4-6 years minimum, leaving almost no margin before 2032. The resolution criterion demands reversal or full arrest of underlying disease—a bar no candidate in any phase of development currently approaches.

A clinically proven cure for dementia is approved before 2032.

A disease-reversing cure for Alzheimer's disease receives FDA approval before 2035.

A definitive cure for at least five major cancers is approved within 10 years.

A definitive cure for cancer is developed and approved within 20 years.

An FDA-approved universal cure for all major forms of cancer is available before 2035.